Cytokines are known to play an important role in the pathogenesis of lupus nephritis (LN) and the Jak/STAT (Janus kinase—signal transducer and activator of transcription factor) pathway is important in mediating signal transduction of cytokines. This study examined the pathogenic role of Jak/STAT signaling in LN. MRL/lpr mice were either treated with a selective Jak2 inhibitor tyrphostin AG490 or with vehicle alone from 12 weeks of age until being sacrificed at week 20. AG490 significantly inhibited the phosphorylation of Jak2 and STAT1 (p < 0.05). Compared with the vehicle-treated mice, AG490 treatment significantly reduced proteinuria, improved renal function and suppressed histological lesions of the kidneys and salivary glands (p < 0.05). AG490 treatment significantly inhibited the renal expression of monocyte chemotactic protein (MCP)-1, interferon (IFN)-γ and class II MHC, which was accompanied by reduced renal infiltration of T cells and macrophages (p < 0.05). In addition, AG490 treatment resulted in a decrease in serum anti-double-stranded DNA (anti-dsDNA) antibody and attenuated the deposition of IgG and C3 in the kidneys (p < 0.05). This study demonstrated that Jak/STAT pathway is implicated in the progression of renal inflammation in MRL/lpr mice and targeting this pathway may provide a potential therapeutic approach for LN.
Adler S., Cohen A., Glassock R.Secondary glomerular diseases. In: Brenner B (ed.), The Kidney. Philadelphia, PA : Saunders; 1996. p. 1498-1516.
2.
Aringer M., Smolen JSCytokine expression in lupus kidneys. Lupus2005; 14: 13-18.
3.
Uhm WS, Na K., Song GW, et al. Cytokine balance in kidney tissue from lupus nephritis patients . Rheumatology (Oxford) 2003; 42: 935-938.
4.
Schwarting A. , Wada T., Kinoshita K., Tesch G., Kelley VRIFN-gamma receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Fas(lpr) mice. J Immunol1998; 161: 494-503.
5.
Fan X., Wuthrich RPUpregulation of lymphoid and renal interferon-gamma mRNA in autoimmune MRL-Fas(lpr) mice with lupus nephritis. Inflammation1997 ; 21: 105-112.
6.
Carvalho-Pinto CE, Garcia MI, Mellado M., et al. Autocrine production of IFN-gamma by macrophages controls their recruitment to kidney and the development of glomerulonephritis in MRL/lpr mice. J Immunol2002; 169: 1058-1067.
7.
Gough DJ, Levy DE, Johnstone RW, Clarke CJIFNgamma signaling-does it mean JAK-STAT?Cytokine Growth Factor Rev2008; 19: 383-394.
8.
Darnell Jr JESTATs and gene regulation. Science1997; 277: 1630-1635.
9.
Imada K., Leonard WJThe Jak-STAT pathway. Mol Immunol2000; 37: 1-11.
10.
Durbin JE, Hackenmiller R., Simon MC, Levy DETargeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell1996; 84: 443-450.
11.
Meraz MA, White JM, Sheehan KC, et al. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell1996; 84: 431-442.
12.
Schindler C. , Strehlow I.Cytokines and STAT signaling. Adv Pharmacol2000; 47: 113-174.
13.
Kisseleva T. , Bhattacharya S., Braunstein J., Schindler CWSignaling through the JAK/STAT pathway, recent advances and future challenges. Gene2002; 285: 1-24.
14.
Gadina M., Hilton D., Johnston JA, et al. Signaling by type I and II cytokine receptors: ten years after . Curr Opin Immunol2001; 13: 363-373.
15.
Dong J., Wang QX, Zhou CY, Ma XF, Zhang YCActivation of the STAT1 signalling pathway in lupus nephritis in MRL/lpr mice . Lupus2007; 16: 101-109.
16.
Martinez-Lostao L., Ordi-Ros J., Balada E., et al. Activation of the signal transducer and activator of transcription-1 in diffuse proliferative lupus nephritis . Lupus2007; 16: 483-488.
17.
Luo C., Laaja P.Inhibitors of JAKs/STATs and the kinases: a possible new cluster of drugs . Drug Discov Today2004; 9: 268-275.
18.
Ghoreschi K. , Laurence A., O’Shea JJSelectivity and therapeutic inhibition of kinases: to be or not to be?Nat Immunol2009 ; 10: 356-360.
19.
Muraoka M., Hasegawa H., Kohno M., et al. IK cytokine ameliorates the progression of lupus nephritis in MRL/lpr mice. Arthritis Rheum2006; 54: 3591-3600.
20.
Yang N., Isbel NM, Nikolic-Paterson DJ, et al. Local macrophage proliferation in human glomerulonephritis. Kidney Int1998; 54: 143-151.
21.
Atkinson C. , Qiao F., Song H., Gilkeson GS, Tomlinson S.Low-dose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease in MRL/lpr mice. J Immunol2008; 180: 1231-1238.
22.
Bao L., Haas M., Kraus DM, Hack BK, et al. Administration of a soluble recombinant complement c3 inhibitor protects against renal disease in MRL/lpr mice. J Am Soc Nephrol2003; 14: 670-679.
23.
Isenberg D. , Smeenk R.Clinical laboratory assays for measuring anti-dsDNA antibodies Where are we now?Lupus2002; 11: 797-800.
24.
Segerer S., Nelson PJ, Schlondorff D.Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies. J Am Soc Nephrol2000; 11: 152-176.
25.
Perez de Lema G., Maier H., Nieto E., et al. Chemokine expression precedes inflammatory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine lupus nephritis. J Am Soc Nephrol2001; 12: 1369-1382.
26.
Wada T., Yokoyama H., Su SB, et al. Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis. Kidney Int1996; 49: 761-767.
27.
Hasegawa H. , Kohno M., Sasaki M., et al. Antagonist of monocyte chemoattractant protein 1 ameliorates the initiation and progression of lupus nephritis and renal vasculitis in MRL/lpr mice. Arthritis Rheum2003; 48: 2555-2566.
28.
Bian ZM, Elner VM, Yoshida A., Kunkel SL, Elner SGSignaling pathways for glycated human serum albumin-induced IL-8 and MCP-1 secretion in human RPE cells. Invest Ophthalmol Vis Sci2001; 42: 1660-1668.
29.
Burysek L., Syrovets T., Simmet T.The serine protease plasmin triggers expression of MCP-1 and CD40 in human primary monocytes via activation of p38 MAPK and Janus kinase (JAK)/STAT signaling pathways. J Biol Chem2002; 277: 33509-33517.
30.
Kim OS, Park EJ, Joe EH, Jou I.JAK-STAT signaling mediates gangliosides-induced inflammatory responses in brain microglial cells. J Biol Chem2002; 277: 40594-40601.
31.
Steimle V., Siegrist CA, Mottet A., Lisowska-Grospierre B., Mach B.Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science1994; 265: 106-109.
32.
Yokoyama H. , Takabatake T., Takaeda M., et al. Up-regulated MHC-class II expression and gamma-IFN and soluble IL-2R in lupus nephritis. Kidney Int1992; 42: 755-763.
33.
Wuthrich RP , Yui MA, Mazoujian G., Nabavi N., Glimcher LH, Kelley VEEnhanced MHC class II expression in renal proximal tubules precedes loss of renal function in MRL/lpr mice with lupus nephritis. Am J Pathol1989; 134: 45-51.
34.
Nagarajan UM , Bushey A., Boss JMModulation of gene expression by the MHC class II transactivator. J Immunol2002; 169: 5078-5088.
35.
van den Elsen PJ, van der Stoep N., Vietor HE, Wilson L., van Zutphen M., Gobin SJLack of CIITA expression is central to the absence of antigen presentation functions of trophoblast cells and is caused by methylation of the IFN-gamma inducible promoter (PIV) of CIITA. Hum Immunol2000; 61: 850-862.
36.
Barbaro Ade L. , Tosi G., Frumento G., et al. Block of Stat-1 activation in macrophages phagocytosing bacteria causes reduced transcription of CIITA and consequent impaired antigen presentation. Eur J Immunol2002; 32: 1309-1318.
37.
Lee SJ, Qin H., Benveniste ENThe IFN-gamma-induced transcriptional program of the CIITA gene is inhibited by statins. Eur J Immunol2008; 38: 2325-2336.
38.
Kelley VE, Roths JBInteraction of mutant lpr gene with background strain influences renal disease . Clin Immunol Immunopathol1985; 37: 220-229.
39.
Bright JJ, Du C., Sriram S.Tyrphostin b42 inhibits IL-12-induced tyrosine phosphorylation and activation of Janus kinase-2 and prevents experimental allergic encephalomyelitis. J Immunol1999; 162: 6255-6262.
40.
Karonitsch T., Feierl E., Steiner CW, et al. Activation of the interferon-gamma signaling pathway in systemic lupus erythematosus peripheral blood mononuclear cells. Arthritis Rheum2009; 60: 1463-1471.
